IMMUNOLOGY TODAY

© 1998 Elsevier Science Ltd.

All rights reserved. No part of this publication may be translated, reproduced, stored in an electronic retrieval system, published or transmitted, in any form or by any means, such as but not limited to, electronic, mechanical, photocopying, recording or otherwise, without the prior written permission of the copyright owner and the Publisher, Elsevier Trends Journals, 68 Hills Road, Cambridge, UK CB2 1LA.

Photocopying: Single photocopies of single articles may be made for personal use as allowed by national copyright laws. Permission of the Publisher and payment of a fee is required for all other photocopying, including multiple or systematic copying, copying for advertising or promotional purposes, resale, and all forms of document delivery. Special rates are available for educational institutions that wish to make photocopies for non-profit educational classroom use. In the USA, users may clear permissions and make payment through the Copyright Clearance Center Inc., 222 Rosewood Drive, Danvers, MA 01923, USA. In the UK, users may clear permissions and make payment through the Copyright Licensing Agency Rapid Clearance Service (CLARCS). In other countries where a local copyright clearance centre exists, please contact it for information on required permissions and payments.

Derivative Works: Subscribers may reproduce tables of contents or prepare lists of articles including abstracts for internal circulation within their institutions. Permission of the Publisher is required for resale or distribution outside the institution. Permission of the Publisher is required for all other derivative works, including compilations and translations.

Electronic Storage: Permission of the Publisher is required to store electronically any material contained in this journal, including any article or part of an article. Contact the Publisher at the address indicated.

Special regulations for authors: Upon acceptance of an article by the journal, the author(s) will be asked to transfer copyright of the article to the Publisher. This transfer will ensure the widest possible dissemination of information.

Notice: No responsibility is assumed by the Publisher for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products, instructions or ideas contained in the material herein. Because of rapid advances in the medical sciences, independent verification of diagnoses and drug dosages should be made.

The Copyright Clearance Center fee code for *Immunology Today* is 0167-4919/98/$19.00.

Published by:
Elsevier Trends Journals,
68 Hills Road,
Cambridge.
UK CB2 1LA.

Printed in the United Kingdom.

IMMUNOLOGY TODAY

Advisory Editorial Board
J.D. Ashwell, *Bethesda, USA*
F.H. Bach, *Harvard, USA*
J.F. Bach, *Paris, France*
T. Boon, *Brussels, Belgium*
C.A. Janeway, Jr, *New Haven, USA*
T. Kishimoto, *Osaka, Japan*
D. Mathis, *Strasbourg, France*
F. Melchers, *Basel, Switzerland*
T. Mosmann, *Edmonton, Canada*
G.J.V. Nossal, *Melbourne, Australia*
A. Rao, *Boston, USA*
K.B.M. Reid, *Oxford, UK*
E. Simpson, *Harrow, UK*
R. Zinkernagel, *Zürich, Switzerland*

Editor Robert Brines

Assistant Editors Louise Walsh and Kirsty McCormack

Editorial Administrators Tracy-Ann Smith and Helen Steele

Publisher Peter Desmond

REFERENCE EDITION
Volume 19
1998

ELSEVIER TRENDS JOURNALS

© Elsevier Science Ltd

IMMUNOLOGY TODAY – REFERENCE EDITION
Published by Elsevier Trends Journals

The reference edition of *Immunology Today* is a compilation of the regular monthly magazine edition. For citation purposes, the page numbers of reprinted articles are common to both editions.

Aims and Scope

The aim of *Immunology Today* is twofold: it plays an essential role in monitoring advances in the various fields of immunology and in bringing together the results in a readable and lucid form. Succinct review articles form the backbone of each monthly issue and, together with the other sections of the magazine (*Update*, *Trends*, *Letters*, *Book Reviews*, centrefolds), they give the reader a complete picture of the diverse field of immunology. Second, the *Viewpoint* section of *IT* acts as a sounding board for new hypotheses and learned speculation on all aspects of the immune system. It is THE forum for new ideas in immunology.

Editorial Policy

Articles in *Immunology Today* are usually commissioned by the Editor. Prospective authors who wish to write should approach the Editor with a brief outline of their proposed article. The Editor will decide whether to commission the article, and will issue instructions for manuscript preparation. Authors should note that manuscripts may be rejected by the peer and editorial review process: commissioning does not guarantee publication.

Editor

Robert Brines PhD, Elsevier Trends Journals, 68 Hills Road, Cambridge, UK CB2 1LA. Tel: +44 1223 315961; Fax: +44 1223 464430, +44 1223 321410; e-mail: IT@elsevier.co.uk

Immunology Today is apolitical. The views and opinions expressed by its writers and correspondents do not necessarily reflect those of the Editorial Staff, the Editorial Board or the Publisher.

IMMUNOLOGY TODAY

REFERENCE EDITION

Volume 19

1998

CONTENTS

January

page

UPDATE

Current literature 1

TRENDS

Can combined T-cell- and antibody-based immunotherapy outsmart tumor cells? *H. Abken, A. Hombach, U. Reinhold and S. Ferrone* 2

Asthma: recent advances *G. Marone* 5

VIEWPOINT

HIV-induced decline in blood CD4/CD8 ratios: viral killing or altered lymphocyte trafficking? *Y.J. Rosenberg, A.O. Anderson and R. Pabst* 10

Beyond inflammation: site-directed immunotherapy *L.A. Lampson* 17

γδ T cells, allergen recognition and airway inflammation *F. Spinozzi, E. Agea, O. Bistoni, N. Forenza and A. Bertotto* 22

Immunological ignorance of silent antigens as an explanation of tumor evasion *L. Chen* 27

Lymphocyte granule-mediated apoptosis: matters of viral mimicry and deadly proteases *C.J. Froelich, V.M. Dixit and X. Yang* 30

REVIEW

Immunoregulatory mechanisms involved in elicitation of allergic contact hypersensitivity *S. Grabbe and T. Schwarz* 37

Rapid $CD4^+$ T-cell turnover in HIV-1 infection: a paradigm revisited *K.C. Wolthers, H. Schuitemaker and F. Miedema* 44

COMMENT

Letters 49

Book Reviews 50

February

UPDATE

Current literature 53

TRENDS

Ancestral immunity comes of age *K.E. Magor and G.R. Vasta* 54

Complement component C1 and the collectins: parallels between routes of acquired and innate immunity *K.B.M. Reid, M.G. Colomb and M. Loos* 56

VIEWPOINT

$CD4^+$ T-cell memory, CD45R subsets and the persistence of antigen – a unifying concept *E.B. Bell, S.M. Sparshott and C. Bunce* 60

Murine B lymphopoiesis: towards a unified model *D.G. Osmond, A. Rolink and F. Melchers* 65

Immunodominant minor histocompatibility antigens: the major ones *C. Perreault, D.C. Roy and C. Fortin* 69

Interleukin 15: a proinflammatory role in rheumatoid arthritis synovitis *I.B. McInnes and F.Y. Liew* 75

REVIEW

Signal transduction through NF-κB *M.J. May and S. Ghosh* 80

Gene vaccination: plasmid DNA is more than just a blueprint *H. Tighe, M. Corr, M. Roman and E. Raz* 89

COMMENT

Letters 97

March

UPDATE

Current literature 99

TRENDS

Cutaneous malignant lymphomas *S. Jahn, K. Asadullah, P. Walden and W. Sterry* 100

Gene therapy in the treatment of autoimmune disease *P.M. Mathisen and V.K. Tuohy* 103

CD5 and other superantigens as 'ticklers' of the B-cell receptor *R. Pospisil and R.G. Mage* 106

Much ado about minor histocompatibility antigens *E. Simpson, D. Roopenian and E. Goulmy* 108

VIEWPOINT

Give us this day our daily germs *G.A.W. Rook and J.L. Stanford* 113

The possible role of bacterial superantigens in the pathogenesis of autoimmune disorders *J. Schiffenbauer, J. Soos and H. Johnson* 117

Fas–FasL interactions: a common pathogenetic mechanism in organ-specific autoimmunity *R. De Maria and R. Testi* 121

REVIEW

Towards development of T-cell vaccines *C.A. Bona, S. Casares and T-D. Brumeanu* 126

Allergic and autoimmune reactions to xenobiotics: how do they arise? *P. Griem, M. Wulferink, B. Sachs, J.B. González and E. Gleichmann* 133

COMMENT

Letters 142

Book Review 145

April

UPDATE

Current literature 147

TRENDS

Mucosal immunology and the eye *M. Zierhut, C.O. Elson, J.V. Forrester, A. Kijlstra, J-P. Kraehenbuhl and D.A. Sullivan* 148

Immunity in early life *J. Kovarik and C-A. Siegrist* 150

VIEWPOINT

Regulation of KIR expression in human T cells: a safety mechanism that may impair protective T-cell responses *M.C. Mingari, A. Moretta and L. Moretta* 153

How the MHC selects Th1/Th2 immunity *J.S. Murray* 157

Probing degeneracy in T-cell recognition using peptide combinatorial libraries *B. Hemmer, M. Vergelli, C. Pinilla, R. Houghten and R. Martin* 163

Inhibition of leukocyte adhesion: an alternative mechanism of action for anti-inflammatory drugs *F. Díaz-González and F. Sánchez-Madrid* 169

REVIEW

Immune responses to dietary antigens: oral tolerance *S. Strobel and A. McI. Mowat* 173

The molecular basis of leukocytosis *G. Opdenakker, W.E. Fibbe and J. Van Damme* 182

COMMENT

Letters 190

Book Review 194

May

UPDATE

Current literature 195

TRENDS
Mechanisms of drug allergy *J.W. Coleman and M. Blanca* 196
Phosphatases and kinases in lymphocyte signaling *H. Yakura* 198
Involvement of the immune system in TSE pathogenesis *N.A. Mabbott, C.F. Farquhar, K.L. Brown and M.E. Bruce* 201
Exercise immunology: integration and regulation *B. Klarlund Pedersen and D.C. Nieman* 204
Xenotransplantation: steps towards a clinical reality *N.J. Rogers, A. Dorling and M. Moore* 206
High-avidity autoantibodies to cytokines *K. Bendtzen, M.B. Hansen, C. Ross and M. Svenson* 209

VIEWPOINT
The peptide-binding strategy of the MHC class II I-A molecules *B. Reizis, M. Eisenstein, F. Mor and I.R. Cohen* 212
Modulation of the immunogenicity of antigenic determinants by their flanking residues *K.D. Moudgil, E.E. Sercarz and I.S. Grewal* 217
Superantibody activities: new players in innate and adaptive immune responses *H. Kohler and S. Paul* 221

REVIEW
Qualitative and quantitative aspects of haematopoietic cell development in the mammalian embryo *E. Dzierzak, A. Medvinsky and M. de Bruijn* 228
Developmental changes in the differentiation capacity of haematopoietic stem cells *C. Bonifer, N. Faust, H. Geiger and A.M. Müller* 236

June

UPDATE
Current literature 243

TRENDS
Fat chance of immunomodulation *P.C. Calder* 244
Tumour immunology: false hopes – new horizons? *A.B. Alexandroff, R.A. Robins, A. Murray and K. James* 247
Pediatric rheumatology: autoimmune mechanisms and therapeutic strategies *J.B. Kümmerle-Deschner, M.K. Hoffmann, D. Niethammer and G.E. Dannecker* 250
Innate T-cell immunity to nonpeptidic antigens *F. Poccia, M-L. Gougeon, M. Bonneville, M. Lôpez-Botet, A. Moretta, L. Battistini, M. Wallace, V. Colizzi and M. Malkovsky* 253

VIEWPOINT
CD1-restricted T cells and resistance to polysaccharide-encapsulated bacteria *R.M. Fairhurst, C-X. Wang, P.A. Sieling, R.L. Modlin and J. Braun* 257
Collagen receptor signalling in platelets: extending the role of the ITAM *S.P. Watson and J. Gibbins* 260
Enkelytin and opioid peptide association in invertebrates and vertebrates: immune activation and pain *G.B. Stefano, B. Salzet and G.L. Fricchione* 265
Gap junctions: a novel route for direct cell–cell communication in the immune system? *L.A. Alves, A.C. Campos de Carvalho and W. Savino* 269

REVIEW
Preferential expression of TCR Vα regions in CD4/CD8 subsets: class discrimination or co-receptor recognition? *B-C. Sim, D. Lo and N.R.J. Gascoigne* 276
The role of endosomes and lysosomes in MHC class II functioning *H.J. Geuze* 282

COMMENT
Letters 288

July

TRENDS
Apoptosis: potential for disease therapies *J-P. Revillard, L. Adorini, M. Goldman, D. Kabelitz and H. Waldmann* 291
Gene therapy of cancer *F. Farzaneh, U. Trefzer, W. Sterry and P. Walden* 294
Bugs on trial: the case of *Helicobacter pylori* and autoimmunity *B.J. Appelmelk, G. Faller, D. Claeys, T. Kirchner and C.M.J.E. Vandenbroucke-Grauls* 296
New approaches in vaccine development *C. Leclerc and J. Ronco* 300

VIEWPOINT

Do heat shock proteins control the balance of T-cell regulation in inflammatory diseases? *W. van Eden, R. van der Zee, A.G.A. Paul, B.J. Prakken, U. Wendling, S.M. Anderton and M.H.M. Wauben* 303

Shared regulatory elements in the promoters of MHC class I and class II genes *P.J. van den Elsen, A. Peijnenburg, M.C.J.A. van Eggermond and S.J.P. Gobin* 308

A mite subversive: cleavage of CD23 and CD25 by Der p 1 enhances allergenicity *F. Shakib, O. Schulz and H. Sewell* 313

REVIEW

Cytotoxic T lymphocytes in HIV-1 infection: a killing paradox? *M.R. Klein, S.H. van der Burg, O. Pontesilli and F. Miedema* 317

The genetics and complexity of allergy and asthma *K.C. Barnes and D.G. Marsh* 325

COMMENT

Letters 333

Book Reviews 335

August

UPDATE

Current literature 337

TRENDS

Not just another meeting: the coming of age of JAKs and STATs *E.H. Chen, M. Gadina, J. Galon, M. Chen and J.J. O'Shea* 338

Selenium: an essential element for immune function *R.C. McKenzie, T.S. Rafferty and G.J. Beckett* 342

VIEWPOINT

The acquisition of host-encoded proteins by nascent HIV-1 *M.J. Tremblay, J-F. Fortin and R. Cantin* 346

The female X-inactivation mosaic in systemic lupus erythematosus *J.J. Stewart* 352

A role for Th1 and Th2 cells in the immunopathogenesis of atopic dermatitis *M. Grewe, C.A.F.M. Bruijnzeel-Koomen, E. Schöpf, T. Thepen, A.G. Langeveld-Wildschut, T. Ruzicka and J. Krutmann* 359

REVIEW

The CD1 family of lipid antigen-presenting molecules *S.A. Porcelli, B.W. Segelke, M. Sugita, I.A. Wilson and M.B. Brenner* 362

Cross-presentation: a general mechanism for CTL immunity and tolerence *F.R. Carbone, C. Kurts, S.R.M. Bennett, J.F.A.P. Miller and W.R. Heath* 368

Cannabinoid receptors and immunity *T.W. Klein, C. Newton and H. Friedman* 373

COMMENT

Book Review 382

September

UPDATE

Current literature 383

TRENDS

APECED: a monogenic autoimmune disease providing new clues to self-tolerance *P. Peterson, K. Nagamine, H. Scott, M. Heino, J. Kudoh, N. Shimizu, S.E. Antonarakis and K.J.E. Krohn* 384

Gene therapy in osteoarticular diseases: where are we? *C. Jorgensen and S. Gay* 387

Rocking the foundations of solid tumor growth by attacking the tumor's blood supply *G. Molema and A.W. Griffioen* 392

VIEWPOINT

A very high level of crossreactivity is an essential feature of the T-cell receptor *D. Mason* 395

Tumors express both unique TSTA and crossprotective 44 kDa oncofetal antigen *J.H. Coggin, Jr, A.L. Barsoum and J.W. Rohrer* 405

Dialogue between the CNS and the immune system in lymphoid organs *R.H. Straub, J. Westermann, J. Schölmerich and W. Falk* 409

REVIEW
Immunology of the tonsils *M. Perry and A. Whyte* 414
Human marginal-zone B cells *J. Spencer, M.E. Perry and D.K. Dunn-Walters* 421

COMMENT
Letters 427
Book Reviews 430

October

UPDATE
The 10th International Congress of Immunology; The immunology of reproduction: update 1998; The major histocompatibility complex – progress and perspectives; Current trends in autoimmune diseases; Continuing education in immunology 431

TRENDS
Induction and modulation of gastrointestinal inflammation *A. Stallmach, W. Strober, T.T. MacDonald, H. Lochs and M. Zeitz* 438
Deciphering the early-response transcription factor networks in mast cells *H. Nechushtan and E. Razin* 441
Transplantation treatment for diabetes *R.M. Smith and T.E. Mandel* 444

VIEWPOINT
The evolution of self-tolerance: a new cell arises to meet the challenge of self-reactivity *B. Fazekas de St Groth* 448
CD4 dimerization and oligomerization: implications for T-cell function and structure-based drug design *S. Li, T. Satoh, R. Korngold and Z. Huang* 455
Granulomatous inflammation and the transmission of infection: schistosomiasis – and TB too? *M.J. Doenhoff* 462
T-cell anergy and altered T-cell receptor signaling: effects on autoimmune disease *K.V. Salojin, J. Zhang, J. Madrenas and T.L. Delovitch* 468

REVIEW
Anti-apoptotic strategies of lymphotropic viruses *E. Meinl, H. Fickenscher, M. Thome, J. Tschopp and B. Fleckenstein* 474
B-cell development: a comparison between mouse and man *P. Ghia, E. ten Boekel, A.G. Rolink and F. Melchers* 480

COMMENT
Letters 486
Book Review 487

November

UPDATE
Balancing the Th1/Th2 concept in multiple sclerosis 489

TRENDS
Novel human immunodeficiencies reveal the essential role of type-1 cytokines in immunity to intracellular bacteria *T.H.M. Ottenhoff, D. Kumararatne and J-L. Casanova* 491
T helper cell differentiation in multiple sclerosis and autoimmunity *R. Martin, N.H. Ruddle, S. Reingold and D.A. Hafler* 495
Scleroderma: immunopathogenesis and treatment *N.R. Rose and N. Leskovsek* 499

VIEWPOINT
CD40 and epithelial cells: across the great divide *L.S. Young, A.G. Eliopoulos, N.J. Gallagher and C.W. Dawson* 502
Neutrophil–Kupffer-cell interaction in host defenses to systemic infections *S.H. Gregory and E.J. Wing* 507
The dynamic structure of the germinal center *S.A. Camacho, M.H. Kosco-Vilbois and C. Berek* 511
Chronic rejection and chronic cyclosporin toxicity in renal allografts *M. Pascual, R.D. Swinford, J.R. Ingelfinger, W.W. Williams, A.B. Cosimi and N. Tolkoff-Rubin* 514
Complement diversity: a mechanism for generating immune diversity? *J.O. Sunyer, I.K. Zarkadis and J.D. Lambris* 519

REVIEW
Tapping the potential of molecular libraries in functional genomics *C.A.K. Borrebaeck* 524
HIV infection: how effective is drug combination treatment? *Z. Grossman, M. Feinberg, V. Kuznetsov, D. Dimitrov and W. Paul* 528

COMMENT
Letters 533
Book Reviews 535

December

TRENDS
Is Wiskott–Aldrich syndrome a cell trafficking disorder? *A.J. Thrasher, G.E. Jones, C. Kinnon, P.M. Brickell and D.R. Katz* 537
HLA and cancer: from research to clinical impact *F. Ruiz-Cabello and F. Garrido* 539
HIV-1 Tat: a polypeptide for all seasons *A. Rubartelli, A. Poggi, R. Sitia and M.R. Zocchi* 543

VIEWPOINT
The Roman god Janus: a paradigm for the function of CD43 *J.R. Ostberg, R.K. Barth and J.G. Frelinger* 546
Non-traditionally derived CTL epitopes: exceptions that prove the rules? *S-M. Mayrand and W.R. Green* 551
Nitric oxide in autoimmune disease: cytotoxic or regulatory mediator? *H. Kolb and V. Kolb-Bachofen* 556
Catecholaminergic suppression of immunocompetent cells *J. Bergquist, A. Tarkowski, A. Ewing and R. Ekman* 562

REVIEW
Chemokines and chemokine receptors in T-cell priming and Th1/Th2-mediated responses *F. Sallusto, A. Lanzavecchia and C.R. Mackay* 568
The organization of mature T-cell pools *C. Tanchot and B. Rocha* 575
Why are there two rat TAPs? *E. Joly and G.W. Butcher* 580

COMMENT
Book Review 586
Letters 586

AUTHOR INDEX 591
SUBJECT INDEX 597
INDEX OF BOOKS REVIEWED 603